Immuron Limited announced the appointment of Dr. Dan Peres as Chief Medical Officer. Dr. Peres will be responsible for leading and managing the company's clinical development programs with a preliminary focus on COVID-19. Dr. Peres was previously engaged by Immuron to manage the company sponsored NASH phase II clinical trial.